Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma

Affiliations

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Comment

Giuseppe Procopio et al. Lancet Oncol. 2020 Dec.

. 2020 Dec;21(12):1538-1539.

doi: 10.1016/S1470-2045(20)30482-4. Epub 2020 Oct 23.

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy. Electronic address: giuseppe.procopio@istitutotumori.mi.it.
² Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

No abstract available

Comment on

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23. Lancet Oncol. 2020. PMID: 33284113 Clinical Trial.